Abstract
Abstract : Since the early 2000s, health professionals increasingly are concerned about Acinetobacter species infections due to demonstrated ability to develop resistance to multiple antibiotics, limiting treatment options. In 2013, Acinetobacter incidence was 5.5 and 4.4 per 100,000 persons per year in the Department of the Navy (DON) and the Department of Defense (DOD), respectively, continuing previously observed descending trends. Active duty Marines had a higher prevalence rate than any other group of service members. A. baumannii was the most common etiologic agent in 2013 was, differing slightly from 2012. In the DON, a negligible increase in overall resistance was noted, though there was an increase in XDR cases. For non-MDR cases in the DON and DOD, providers often prescribed trimethoprim/sulfamethoxazole, consistent with 2012 observations. For MDR/XDR cases in 2013, DON providers most commonly prescribed colistin, minocycline, piperacillin/tazobactam, and trimethoprim/sulfamethoxazole. DOD providers most commonly prescribed ciprofloxacin for these cases. Although different from 2012, 2013 prescribing patterns were consistent with recommendations. Among DON and DOD beneficiaries respectively, organisms were most susceptible to cefepime and gentamicin while least susceptible to ampicillin and nitrofurantoin; consistent with observations for the DON and DOD from 2012.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
